

CH

FORM

**FILED**  
**MAY 14 2008**  
**MAY 14 2008**

[ADD: CASE HEADING]

**Judge David H. Coar**  
**United States District Court**

REPORT OF PARTIES' PLANNING CONFERENCE

Pursuant to this court's order,

representing plaintiff(s), and

representing the defendant(s), met on

pursuant to Rule 26(f) to discuss:

Heisner v. Genzyme

No. 08CS93

Judge Coar

- (1) the nature and basis of their claims and defenses;
- (2) the possibilities for a prompt settlement or resolution of this case;
- (3) to make or arrange for the disclosures required under Rule 26(a)(1); and
- (4) to develop a discovery plan.

To that end, the parties propose the following:

A. The issues in this case may be simplified by taking the following steps:

1. Subject to motion to dismiss, issues will be
2. Simplified or eliminated.
- 3.
- 4.
- 5.

B. The following modifications to the discovery requirements of the Federal Rules of Civil Procedure or Local Rules should be made in order to expedite discovery:

1. At this time, none suggested.
- 2.
- 3.
- 4.
- 5.

C. Discovery will be needed on the following subjects:

1. To extent claims remain after
2. motion to dismiss is decided;
3. Liability
4. Defenses
- Damages.

D. Discovery should should not be conducted in phases for Expert Discovery

E. Discovery is likely to be contentious and management of discovery should be referred to the Magistrate Judge. Yes \_\_\_\_\_ No ✓

F. The parties consent do not consent to this matter being referred to the Magistrate Judge for final disposition.

G. The parties have discussed the possibility of alternative dispute resolution and concluded:

At this stage, not feasible

H. The parties have discussed a prompt settlement or other resolution of this matter. At this stage,  
The plaintiff has made a written demand of \$ \_\_\_\_\_, and the not,  
defendant has offered \$ \_\_\_\_\_ feasible.

I. The Court should consider the following methods of expediting the resolution of this matter:

[Signature]  
Attorney for Plaintiff

[Signature]  
Attorney for Defendant  
Genzyme Corporation